IDIOPATHIC PULMONARY FIBROSIS

This study tests an experimental drug called SB17170 in 30 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The goal is to see if the drug can improve lung function compared to a placebo over 12 weeks. Participants will …

This study tests a new medicine called BI 765423 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 71 adults aged 40 and older will receive either the study drug or a placebo by IV every four weeks for 3 month…

This study tests an oral drug called H01 (hymecromone) in 37 adults with interstitial lung disease, a condition that causes lung scarring and often leads to death within 3-5 years. Participants take the drug twice daily for 12 weeks. The goal is to see if H01 can lower a marker o…

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants must have completed a previous study with the same drug. The goal is to see if the drug is safe …

This study tests an experimental pill called PIPE-791 in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 324 adults aged 40 and older will receive either the drug or a placebo to see if it helps preserve lung functio…

This early-phase study tests if a lung transplant before a bone marrow transplant can safely restore both lung and blood function in people with end-stage lung disease (like pulmonary fibrosis or COPD) and bone marrow failure. Up to 8 adults aged 18-60 will receive a lung transpl…

This study tests an oral medication called ifetroban in 128 adults aged 40+ with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants will receive either ifetroban or a placebo for 52 weeks to see if the drug can slow the decline in lung function…

This study tests an experimental drug called MTX-463 in 164 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants will receive either the drug or a placebo to see if MTX-463 can slow the decline in lung functio…

This study tests an experimental drug called ABBV-142 for idiopathic pulmonary fibrosis (IPF), a rare disease that scars the lungs and makes breathing hard. About 165 adults with IPF will receive either ABBV-142 or a placebo for 52 weeks to see if it safely slows lung function de…

This early-stage study tests whether artesunate, a drug used for malaria, is safe for people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing problems. About 15 adults aged 40 and older with IPF will receive either artesunate or …

This study tests whether lansoprazole, a drug that reduces stomach acid, can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 298 adults with IPF from UK hospitals will take either lansoprazole or a placebo twice daily for 12 mon…

This study tests whether adding the antibiotic azithromycin to usual care can help people hospitalized with a sudden worsening of idiopathic pulmonary fibrosis (IPF). About 30 adults with mild to moderate IPF will be randomly assigned to receive either azithromycin plus standard …

This study tests whether adding intravenous immunoglobulin (IVIG) to standard care helps people hospitalized with sudden, severe worsening of idiopathic pulmonary fibrosis (IPF). About 196 adults with IPF and an acute flare-up will receive either usual treatment alone or usual tr…

This study tests a drug called senicapoc to see if it can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo for 26 weeks. Re…

This study tests whether taking zinc and nicotinamide riboside (a form of vitamin B3) for 24 weeks can improve symptoms and quality of life in people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease. About 60 participants will take the supplements or a placebo fro…

This early-stage study is testing a drug called nalbuphine ER in 10 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease that makes breathing hard. The goal is to see if the drug is safe and can improve breathing function. Participants will take increasing dos…

This study looks at how pirfenidone, a common IPF medicine, changes the amount of a new drug called BI 1015550 in the blood. About 20 adults with IPF, aged 40 and older, will take one dose of BI 1015550, then pirfenidone for three weeks, and then another dose of BI 1015550. Resea…

This study follows 750 close relatives of people with a rare, inherited form of lung scarring called familial pulmonary fibrosis. Participants have no symptoms yet but carry a higher genetic risk. Researchers will track their health over time with yearly surveys and in-person vis…

This study looks at why people with interstitial lung disease (ILD) often feel short of breath and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 adults with ILD, and test whether extra ox…

This early-stage study looks at how the experimental drug ENV-101 interacts with two standard IPF medicines, nintedanib and pirfenidone, in healthy adults. Researchers will measure drug levels in the blood to understand safety and dosing. The study involves 57 participants across…

This early-stage study tests a new drug, SV001, in 53 healthy Chinese adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a serious lung-scarring disease. This trial does not involve patients with the disease a…

This study looks at whether people with idiopathic pulmonary fibrosis (IPF) have problems in their small airways before starting medication. Researchers will use a simple breathing test called nitrogen washout to check for these issues. About 100 adults with IPF will take part, a…

This study is testing a wearable device called C-mo System that can automatically detect and describe coughs. 300 people aged 2 and older with cough-related conditions like asthma or COPD will wear the device for 24 hours. The goal is to see how well the device can identify cough…

This study is creating a registry and biobank for people with interstitial lung disease (ILD), including sarcoidosis, pulmonary fibrosis, and hypersensitivity pneumonitis. Researchers will collect medical data and biological samples from up to 1,000 participants to better underst…

This study aims to find genetic and protein markers that could predict when a person with idiopathic pulmonary fibrosis (IPF) might experience a rapid decline in lung function. Researchers will collect and analyze samples from 500 adults diagnosed with IPF and compare them to cha…

This early-stage study tests a new medicine called GNS-3545 in 72 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a disease that causes lung scarring. Participants will receive either the drug or a …

This is a very early study to check the safety of a new experimental drug called SRN001 in healthy volunteers. The drug is designed to treat a serious lung scarring disease called idiopathic pulmonary fibrosis, but this first trial is only testing it in healthy men to see how the…